Journal of Renal Nutrition
Volume 6, Issue 3 , Pages 141-151 , July 1996

The effect of diet on hypercholesterolemia in renal transplant recipients

  • Susan S Sullivan, DSc, RD (Clinical Dietitian)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Susan S. Sullivan, DSc, RD, Clinical Dietitian, Department of Dietetics, Massachusetts General Hospital, Fruit St, Boston, MA 02114
    • Department of Dietetics, Massachusetts General Hospital, Fruit St, Boston, MA, USA.
    • ,
  • Ellen J Anderson, MS, RD (Research Dietitian Manager)

      Affiliations

    • Mallinckrodt General Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA.
    • ,
  • Sharon Best, MA (Biostatistician)

      Affiliations

    • Mallinckrodt General Clinical Research Center, Massachusetts General Hospital, Boston, MA, USA.
    • ,
  • Lillian M Sonnenberg, DSc, RD (Senior Manager)

      Affiliations

    • Ambulatory Nutrition Service, Department of Dietetics, Massachusetts General Hospital, Boston, MA, USA.
    • ,
  • Winfred W Williams, MD (Instructor in Medicine)

      Affiliations

    • Harvard Medical School, Boston, MA, USA.
    • Renal Unit, Massachusetts General Hospital, Boston, MA, USA.

References 

  1. Bittar AE, Ratcliffe PJ, Richardson AJ, et al.  The prevalence of hyperlipidemia in renal transplant recipients. Associations with immunosuppressive and antihypertensive therapy. Transplantation. 1990;50:987–992
  2. Costanzo-Nordin MR, Grady KL, Johnson MR, et al.  Long-term effects of cyclosporine-based immunosuppression in cardiac transplantation: The Loyola experience. In: ed 2. Transplant Proc. 22:1990;p. 6–11 (suppl)
  3. Vathsala A, Weinburg RB, Schoenberg L, et al.  Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation. 1989;48:37–43
  4. Drueke TB, Abdulmassih Z, Lacour B, et al.  Atherosclerosis and lipid disorders after renal transplantation. Kidney Int. 1991;39:S24–S28
  5. Markell MS, Friedman EA. Hyperlipidemia after organ transplantation. Am J Med. 1989;87:5-61N–5-67N
  6. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med. 1988;148:36–69
  7. Martin MJ, Hulley SB, Browner WS, et al.  Serum cholesterol, blood pressure, and mortality: Implications from a cohort of 361, 662 men. Lancet. 1986;2:933–936
  8. The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374
  9. Brunner FP, Broyer M, Brynger H, et al.  Survival on renal replacement therapy: Data from the EDTA registry. Nephrol Dial Transplant. 1988;2:109–122
  10. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988;84:985–992
  11. Keane WF, Mulcahy WS, Kasiske BL, et al.  Hyperlipidemia and progressive renal disease. Kidney Int. 1991;39:S41–S48
  12. Moore RA, Callahan MF, Cody M, et al.  The effect of the American Heart Association step one diet on hyperlipidemia following renal transplantation. Transplantation. 1990;49:60–62
  13. Nelson J, Beauregard H, Gelinas M, et al.  Rapid improvement of hyperlipidemia in kidney transplant patients with a multifactorial hypolipidemic diet. In: ed 2. Transplant Proc. 20:1988;p. 1264–1270
  14. Shen SY, Lukens CW, Alongi SV, et al.  Patient profile and effect of dietary therapy on post-transplant hyperlipidemia. Kidney Int. 1983;24:S147–S152 (suppl)
  15. Disler PB, Goldberg RB, Kuhn L, et al.  The role of diet in the pathogenesis and control of hyperlipidemia after renal transplantation. Clin Nephrol. 1981;16:29–34
  16. Trinder P. Oxidase determination of plasma cholesterol as cholest-4-en-3-one using iso-octane extraction. Ann Clin Biochem. 1981;18:64–70
  17. In:  Bergmeyer HU editors. Methods of Enzymatic Analysis. ed 2. New York, NY: Academic Press; 1974;p. 1831
  18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem. 1972;18:499–502
  19. Marschner I, Botterman P, Erhardt F, et al.  Group experiments on the radioimmunological insulin determination. Horm Metab Res. 1974;6:293–296
  20. Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet. II. The effect of cholesterol in the diet. Metabolism. 1965;14:759–765
  21. Lichtenstein AH, Ausman LM, Carrasco W, et al.  Effects of canola, corn, and olive oils on fasting and postprandial plasma lipoproteins in humans as part of a National Cholesterol Education Program Step 2 Diet. Arterioscler Thromb. 1993;13:1533–1542
  22. Dietschy JM, Woollett LA, Spady DK. The interaction of dietary cholesterol and specific fatty acids in the regulation of LDL receptor activity and plasma LDL-cholesterol concentrations. Ann N Y Acad Sci. 1993;676:11–26
  23. Hays AP, Hill RB. Enzymes of lipid synthesis in the liver of the cortisone-treated rat. Biochim Biophys Acta. 1965;98:646–648
  24. Ettinger WH, Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism. 1988;37:1055–1058
  25. Higgins RM, Ratcliffe PJ. Hypercholesterolaemia and vascular disease after transplantation. Transplant Rev. 1991;5:131–149
  26. Kannel WB, Castelli WP, Gordon T. Cholesterol in the prediction of athersclerotic disease: New perspectives based on the Framingham study. Ann Intern Med. 1979;90:85–91
  27. Havel R, McCollum Award Lecture . Triglyceriderich lipoproteins and atherosclerosis—new perspectives. 1993 Am J Clin Nutr. 1994;59:795–799
  28. Versulius DJ, Wenting GJ, Derkx FHM, et al.  Who should be converted from cyclosporine to conventional immunosuppression in kidney transplantation, and why. Transplantion. 1987;44:387–389
  29. Kasiske BL, Tortorice KL, Heim-Duthoy KL, et al.  The adverse impact of cyclosporine on serum lipids in renal transplant recipients. Am J Kidney Dis. 1991;17:700–707
  30. Hricik DE, Mayes JT, Schulak JA. Independent effects of cyclosporine and prednisone on posttransplant hypercholesterolemia. Am J Kidney Dis. 1991;16:353–358
  31. Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporine: Inter- and intra-individual variations and metabolic pathways. In: ed 2. Transplant Proc. 22:1990;p. 1110–1112
  32. Niederberger W, Lemaire M, Maurer G, et al.  Distribution and binding of cyclosporine in blood and tissues. In: ed 2. Transplant Proc. 15:1983;p. 2419–2421
  33. Princen HMG, Meijer P, Hofstee B, et al.  Effects of cyclosporin A (CsA) on LDL-receptor activity and bile acid synthesis in hepatocyte monolayer cultures and in vivo in rat. Hepatology. 1987;7:1109; (abstr)
  34. Krupp P, Monka C. Side-effect profile of cyclosporin A in patients treated for psoriasis. Br J Dermatol. 1990;122:47–56
  35. Lloveras JJ, Durand D, Ader JL, et al.  Comparison between glomerular filtration rate and renal plasma flow between kidney and heart transplant recipients maintained on a similar cyclosporine dosage. In: ed 2. Transplant Proc. 26:1994;p. 248
  36. Bach JF, Feutren G, Noel LH, et al.  Factors predictive of cyclosporine-induced nephrotoxicity: The role of cyclosporine blood levels. In: ed 2. Transplant Proc. 22:1990;p. 1296–1298
  37. Attman PO, Alaupovic P. Lipid abnormalities in chronic renal insufficiency. Kidney Int. 1991;39:S16–S23 suppl 31
  38. Tran ZV, Weltman A. Differential effects of exercise on serum lipid and lipoprotein levels seen with changes in body weight. A meta-analysis. JAMA. 1985;254:919–924
  39. Johnson CP, Gallagher-Lepak S, Zhu YR, et al.  Factors influencing weight gain after renal transplantation. Transplantation. 1993;56:822–827

PII: S1051-2276(96)90052-7

Journal of Renal Nutrition
Volume 6, Issue 3 , Pages 141-151 , July 1996

Article Tools